These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23793769)

  • 21. [Research impulses for personalized cancer therapies].
    Aktuelle Urol; 2013 Sep; 44(5):349. PubMed ID: 24043531
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site.
    Nagasaka M; Kukreja G; Abdulfatah E; Vaishampayan U; Sukari A
    Clin Genitourin Cancer; 2017 Aug; 15(4):e713-e717. PubMed ID: 28024951
    [No Abstract]   [Full Text] [Related]  

  • 23. The genetic make-up of renal cell tumors.
    Noordzij MA; Mickisch GH
    Urol Res; 2004 Aug; 32(4):251-4. PubMed ID: 15497212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions.
    Goldsamt A; Damayanti NP; De Nigris F; Pili R
    Cancer J; 2020; 26(5):399-406. PubMed ID: 32947308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell, gene and vaccine based strategies in kidney cancer.
    Gitlitz BJ; Figlin RA
    Cancer Treat Res; 2003; 116():183-98. PubMed ID: 14650833
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular-based therapies for renal cell carcinoma.
    Zisman A; Pantuck AJ; Belldegrun AS
    Curr Urol Rep; 2001 Feb; 2(1):55-61. PubMed ID: 12084296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer].
    Simonaggio A; Epaillard N; Elaidi R; Sun CM; Moreira M; Oudard S; Vano YA
    Bull Cancer; 2020 Jun; 107(5S):S24-S34. PubMed ID: 32620204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?
    Haake SM; Rathmell WK
    Cancer; 2017 Jan; 123(2):200-209. PubMed ID: 27861752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commentary on: "Comprehensive molecular characterization of papillary renal-cell carcinoma." Cancer Genome Atlas Research Network.: N Engl J Med. 2016 Jan 14;374(2):135-45.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):578-579. PubMed ID: 28780132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular biology in nephrology: an overview with emphasis on the study of renal cancer.
    Cohen HT; Sukhatme VP
    Semin Nephrol; 1992 Nov; 12(6):495-505. PubMed ID: 1335610
    [No Abstract]   [Full Text] [Related]  

  • 31. Decade in review-kidney cancer: discoveries, therapies and opportunities.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2014 Nov; 11(11):614-6. PubMed ID: 25287783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial renal cell carcinoma: review of recent molecular genetics.
    Yao M; Shuin T
    Int J Urol; 1995 May; 2(2):61-70. PubMed ID: 7553290
    [No Abstract]   [Full Text] [Related]  

  • 33. The molecular biology of renal cancer: another piece of the puzzle.
    Stewart GD; Harrison DJ; Berney DM; Powles T
    Eur Urol; 2014 Jul; 66(1):85-6. PubMed ID: 24674147
    [No Abstract]   [Full Text] [Related]  

  • 34. Rational Therapeutic Sequencing in Metastatic Renal Cell Carcinoma: Insights Gained from IMmotion150.
    Singla N
    Eur Urol; 2021 May; 79(5):674-675. PubMed ID: 33608152
    [No Abstract]   [Full Text] [Related]  

  • 35. Conference report--at the forefront of cancer research: clinical results highlights of the annual meeting of the 95th American Association for Cancer Research, March 27-31, 2004; Orlando, Florida.
    Mariani SM
    MedGenMed; 2004 May; 6(2):19. PubMed ID: 15266245
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma.
    Lalani AA; Bakouny Z; Farah S; Donskov F; Dudani S; Heng DYC; Choueiri TK
    JAMA Oncol; 2021 May; 7(5):773-775. PubMed ID: 33662110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial Comment from Dr Kato to Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
    Kato T
    Int J Urol; 2020 Sep; 27(9):797-798. PubMed ID: 32741002
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial Comment from Dr Tsuzuki to Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
    Tsuzuki T
    Int J Urol; 2020 Sep; 27(9):798-799. PubMed ID: 32767498
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary, Metastatic Tumors Vary Genomically by Cancer Type.
    Cancer Discov; 2023 Jul; 13(7):1505-1506. PubMed ID: 37249311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes.
    Sirintrapun SJ; Parwani AV
    Surg Pathol Clin; 2009 Mar; 2(1):199-223. PubMed ID: 26838102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.